338 related articles for article (PubMed ID: 31676591)
21. Simultaneous measurement of the size and methylation of chromosome 4qA-D4Z4 repeats in facioscapulohumeral muscular dystrophy by long-read sequencing.
Hiramuki Y; Kure Y; Saito Y; Ogawa M; Ishikawa K; Mori-Yoshimura M; Oya Y; Takahashi Y; Kim DS; Arai N; Mori C; Matsumura T; Hamano T; Nakamura K; Ikezoe K; Hayashi S; Goto Y; Noguchi S; Nishino I
J Transl Med; 2022 Nov; 20(1):517. PubMed ID: 36348371
[TBL] [Abstract][Full Text] [Related]
22. Facioscapulohumeral muscular dystrophy.
Tawil R
Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
[TBL] [Abstract][Full Text] [Related]
23. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
Haynes P; Bomsztyk K; Miller DG
Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
[TBL] [Abstract][Full Text] [Related]
24. Hemizygosity for SMCHD1 in Facioscapulohumeral Muscular Dystrophy Type 2: Consequences for 18p Deletion Syndrome.
Lemmers RJ; van den Boogaard ML; van der Vliet PJ; Donlin-Smith CM; Nations SP; Ruivenkamp CA; Heard P; Bakker B; Tapscott S; Cody JD; Tawil R; van der Maarel SM
Hum Mutat; 2015 Jul; 36(7):679-83. PubMed ID: 25820463
[TBL] [Abstract][Full Text] [Related]
25. Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.
Greco A; Goossens R; van Engelen B; van der Maarel SM
Clin Genet; 2020 Jun; 97(6):799-814. PubMed ID: 32086799
[TBL] [Abstract][Full Text] [Related]
26. Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.
Hamel J; Tawil R
Neurotherapeutics; 2018 Oct; 15(4):863-871. PubMed ID: 30361930
[TBL] [Abstract][Full Text] [Related]
27. Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2.
Lemmers RJ; van der Vliet PJ; Balog J; Goeman JJ; Arindrarto W; Krom YD; Straasheijm KR; Debipersad RD; Özel G; Sowden J; Snider L; Mul K; Sacconi S; van Engelen B; Tapscott SJ; Tawil R; van der Maarel SM
Eur J Hum Genet; 2018 Jan; 26(1):94-106. PubMed ID: 29162933
[TBL] [Abstract][Full Text] [Related]
28. A proteomics study identifying interactors of the FSHD2 gene product SMCHD1 reveals RUVBL1-dependent DUX4 repression.
Goossens R; Tihaya MS; van den Heuvel A; Tabot-Ndip K; Willemsen IM; Tapscott SJ; González-Prieto R; Chang JG; Vertegaal ACO; Balog J; van der Maarel SM
Sci Rep; 2021 Dec; 11(1):23642. PubMed ID: 34880314
[TBL] [Abstract][Full Text] [Related]
29. Clinical, muscle pathological, and genetic features of Japanese facioscapulohumeral muscular dystrophy 2 (FSHD2) patients with SMCHD1 mutations.
Hamanaka K; Goto K; Arai M; Nagao K; Obuse C; Noguchi S; Hayashi YK; Mitsuhashi S; Nishino I
Neuromuscul Disord; 2016; 26(4-5):300-8. PubMed ID: 27061275
[TBL] [Abstract][Full Text] [Related]
30. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
31. Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2.
Lemmers RJ; Goeman JJ; van der Vliet PJ; van Nieuwenhuizen MP; Balog J; Vos-Versteeg M; Camano P; Ramos Arroyo MA; Jerico I; Rogers MT; Miller DG; Upadhyaya M; Verschuuren JJ; Lopez de Munain Arregui A; van Engelen BG; Padberg GW; Sacconi S; Tawil R; Tapscott SJ; Bakker B; van der Maarel SM
Hum Mol Genet; 2015 Feb; 24(3):659-69. PubMed ID: 25256356
[TBL] [Abstract][Full Text] [Related]
32. Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2.
Mitsuhashi S; Boyden SE; Estrella EA; Jones TI; Rahimov F; Yu TW; Darras BT; Amato AA; Folkerth RD; Jones PL; Kunkel LM; Kang PB
Neuromuscul Disord; 2013 Dec; 23(12):975-80. PubMed ID: 24128691
[TBL] [Abstract][Full Text] [Related]
33. Remotely acting SMCHD1 gene regulatory elements: in silico prediction and identification of potential regulatory variants in patients with FSHD.
Mayes MB; Morgan T; Winston J; Buxton DS; Kamat MA; Smith D; Williams M; Martin RL; Kleinjan DA; Cooper DN; Upadhyaya M; Chuzhanova N
Hum Genomics; 2015 Oct; 9():25. PubMed ID: 26446085
[TBL] [Abstract][Full Text] [Related]
34. SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain.
Lemmers RJLF; van der Stoep N; Vliet PJV; Moore SA; San Leon Granado D; Johnson K; Topf A; Straub V; Evangelista T; Mozaffar T; Kimonis V; Shaw ND; Selvatici R; Ferlini A; Voermans N; van Engelen B; Sacconi S; Tawil R; Lamers M; van der Maarel SM
J Med Genet; 2019 Oct; 56(10):693-700. PubMed ID: 31243061
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory facioscapulohumeral muscular dystrophy type 2 in 18p deletion syndrome.
Renard D; Taieb G; Garibaldi M; Maues De Paula A; Bernard R; Lagha N; Cristofari G; Vovan C; Chaix C; Lévy N; Khau Van Kien P; Sacconi S
Am J Med Genet A; 2018 Aug; 176(8):1760-1763. PubMed ID: 30055030
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Optical Genome Mapping in Clinical Genetic Testing of Facioscapulohumeral Muscular Dystrophy.
Kovanda A; Lovrečić L; Rudolf G; Babic Bozovic I; Jaklič H; Leonardis L; Peterlin B
Genes (Basel); 2023 Nov; 14(12):. PubMed ID: 38136988
[TBL] [Abstract][Full Text] [Related]
37. Cross-sectional Neuromuscular Phenotyping Study of Patients With Arhinia With
Mohassel P; Chang N; Inoue K; Delaney A; Hu Y; Donkervoort S; Saade D; Billioux BJ; Meader B; Volochayev R; Konersman CG; Kaindl AM; Cho CH; Russell B; Rodriguez A; Foster KW; Foley AR; Moore SA; Jones PL; Bonnemann CG; Jones T; Shaw ND
Neurology; 2022 Mar; 98(13):e1384-e1396. PubMed ID: 35121673
[TBL] [Abstract][Full Text] [Related]
38. Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.
Jia FF; Drew AP; Nicholson GA; Corbett A; Kumar KR
Neuromuscul Disord; 2021 Nov; 31(11):1101-1112. PubMed ID: 34711481
[TBL] [Abstract][Full Text] [Related]
39. SMCHD1 and LRIF1 converge at the FSHD-associated D4Z4 repeat and LRIF1 promoter yet display different modes of action.
Šikrová D; Testa AM; Willemsen I; van den Heuvel A; Tapscott SJ; Daxinger L; Balog J; van der Maarel SM
Commun Biol; 2023 Jun; 6(1):677. PubMed ID: 37380887
[TBL] [Abstract][Full Text] [Related]
40. DICER/AGO-dependent epigenetic silencing of D4Z4 repeats enhanced by exogenous siRNA suggests mechanisms and therapies for FSHD.
Lim JW; Snider L; Yao Z; Tawil R; Van Der Maarel SM; Rigo F; Bennett CF; Filippova GN; Tapscott SJ
Hum Mol Genet; 2015 Sep; 24(17):4817-28. PubMed ID: 26041815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
